Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | GSK503 |
Synonyms | |
Therapy Description |
GSK503 selectively inhibits EZH2, resulting in decreased EZH2 methytransferase activity, and potentially leading to reduced tumor growth (PMID: 23680150, PMID: 28228601, PMID: 29732557). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GSK503 | GSK-503|GSK 503 | EZH2 inhibitor 20 | GSK503 selectively inhibits EZH2, resulting in decreased EZH2 methytransferase activity, and potentially leading to reduced tumor growth (PMID: 23680150, PMID: 28228601, PMID: 29732557). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|